A5016889553- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Histone Deacetylase Inhibitors Research
- Virus-based gene therapy research
- Mycobacterium research and diagnosis
- Immunodeficiency and Autoimmune Disorders
- Antifungal resistance and susceptibility
- Mesenchymal stem cell research
- COVID-19 and healthcare impacts
- Hemoglobinopathies and Related Disorders
- Neonatal Health and Biochemistry
- Protein Degradation and Inhibitors
- Methemoglobinemia and Tumor Lysis Syndrome
- Hematological disorders and diagnostics
- COVID-19 Clinical Research Studies
- Nutrition and Health in Aging
- Frailty in Older Adults
Hospital Clínic de Barcelona
2018-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2020-2025
Universitat de Barcelona
2020-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Institut d'Investigacions Biomèdiques de Barcelona
2020
Josep Carreras Leukaemia Research Institute
2020
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive CLL treated ARI-0001 cells, six them Richter's transformation (RT). One patient RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity not observed in any patient. All experienced absolute B-cell aplasia, and seven (87.5%) responded to With a median follow-up 5.6 months, two CD19-negative...
Abstract Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular combinations and overall response (≥1-log reduction MRD) 66 (84%) MRD negativity 56 (71%). Eighteen (23%) required...
Summary European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new classifications published same year. We have retrospectively assessed prognostic value ELN 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 first complete response (CR1) from 2011 2021 our centre. Adverse (Adv) presented inferior outcome terms overall survival (OS) and leukaemia‐free (LFS) (OS [ p =...
Not available.
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated (MMUD, 33.2%), or haploidentical (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, 22.4%, respectively (p =...
Summary Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease no currently available aetiological treatment. We evaluated potential role terminal complement pathway four patients carfilzomib‐induced TMA. Membrane attack complex (C5b‐9) deposition on endothelial cells culture exposed to plasma from during acute phase suggests overactivation as mechanism damage three out patients. If confirmed...
Germ line predisposition in acute myeloid leukemia (AML) has gained attention recent years because of a nonnegligible frequency and an impact on management patients their relatives. Risk alleles for AML development may be present without clinical suspicion hereditary hematologic malignancy syndrome. In this study we investigated the presence germ variants (GVs) 288 genes related to cancer 47 with available paired, tumor-normal material, namely bone marrow stroma cells (n = 29), postremission...
We evaluated outcomes of 18 patients with isolated extramedullary disease (iEMD) relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated the CD19-directed CAR T cells ARI-0001 in two centers (adult and pediatric), including CART19-BE-01 trial consecutive compassionate use program. iEMD was detected by PET-CT 78% (14/18), and/or cerebrospinal fluid analysis 28% (5/18). Patients received cyclophosphamide fludarabine followed 1 × 106 cells/kg, initially as a single dose...
In recent years, important epidemiologic changes have been described in hematopoietic stem cell transplantation (HSCT) recipients with bloodstream infection (BSI), increases gram-negative bacilli and multidrug resistant (MDR) bacilli. These linked to a worrisome increase mortality. We aimed define the risk factors for mortality of HSCT patients experiencing BSI. All episodes BSI between 2008 2017 were prospectively collected. Multivariate analyses performed. A total 402 documented 293 who...
Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid (AML). In a single-center cohort of 219 CMML patients, we explored potential correlation between clinical features, gene mutations, treatment regimens with overall survival (OS) clonal evolution into AML. The most commonly detected mutations were TET2, SRSF2, ASXL1, RUNX1. Median OS was 34 months varied...
Background Autologous stem cell transplantation (ASCT) remains the standard of care for young multiple myeloma (MM) patients; indeed, at-home ASCT has been positioned as an appropriate therapeutic strategy. However, despite use prophylactic antibiotics, neutropenic fever (NF) and hospital readmissions continue to pose most important limitations in outpatient setting. It is possible that febrile episodes may have a non-infectious etiology, engraftment syndrome could play more significant...
Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) its use in different AML settings will be expanded the following years, management of adverse events (AEs) lacks harmonized algorithms during treatment these patients. We have studied incidence relevant AEs 43 patients who achieved a response to VenHMA management. Median overall survival our cohort was 19 months. No discontinued due after C3D1, Regarding severe AEs, high rates grade 4 neutropenia...
Despite the use of fluoroquinolone (FQ) prophylaxis, neutropenic fever (NF) is most frequent cause hospital readmission in ambulatory care programs for patients treated with autologous stem cell transplantation (ASCT). We analyzed impact intensifying primary prophylaxis addition piperacillin/tazobactam (PT) to FQ. Between January 2002 and August 2018, 154 lymphoma conditioned BEAM were included (40% received ceftriaxone (Ct) plus FQ 60% PT FQ). NF required 84 vs. 41% (p < .0001) 12 1% =...